GSK and Alamar will profile more than 60,000 serum samples to see how one diagnosis can hide several diseases.

From brain scans to Super Mario, NeuroAge and TruDiagnostic explain how Younger turns personal health goals into public ...

Eisai’s CTAD slate includes five-year Clarity AD data, a real-world symposium and a look at lecanemab and donanemab dosing.

Built with David Sinclair for Grok Bot, the free multi-agent system turns personal health data into checkable N-of-1 experiments.

SIR2501, a SARM1 blocker with FDA Fast Track status for chemo nerve damage, gets three poster slots in Washington.

A late-breaking slot in Boston will bring fresh data on an experimental drug that aims to turn down tau production in the ...

Ultrahuman’s racing partnership is about more than lap times; the bigger story is the teenage years when female healthspan takes shape.

Employers get one platform for GLP-1 access, hormone therapy and chronic disease coaching, with clinicians still signing off ...

A new review argues that aging has several brakes, not one, and that the way genes are switched may hit the limit first.

Alamar and Nightingale will hunt rare, low-level proteins in UK Biobank blood for signs of dementia and Parkinson’s long ...

Emory researchers say a 10-protein plasma signature outperformed the established marker, though it remains a research finding.

RoC is recruiting at least 30 pairs of women 40 and older for a 12-week study that pairs skin checks with sleep and stress data.